Cystic Fibrosis Foundation Therapeutics Announces $15 Million Research Project for Development of Novel CF Treatment

Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $15 million research agreement with biopharmaceutical company Shire plc to support the development of a new cystic fibrosis treatment targeting the underlying cause of … Continued

Vertex Receives European Approval for KALYDECO (ivacaftor) in Eight Non-G551D Gating Mutations

 Vertex Pharmaceuticals Incorporated today announced that the European Commission has approved KALYDECO™ (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Today’s approval follows … Continued

Vertex Announces Phase 2 Results of Combination Treatment in People with One Copy of the F508del CF Mutation

Vertex Pharmaceuticals Inc. announced results from a Phase 2 clinical trial of the cystic fibrosis drug ivacaftor (Kalydeco™) in combination with another potential therapy, lumacaftor, in people with one copy of the F508del mutation, ages 18 and older. In the … Continued

Positive results from Vertex F508del Phase 3 Study with Lumacaftor in Combination with Ivacaftor

Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation Combination of lumacaftor and ivacaftor … Continued